According to our latest study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 – COVID-19 Impact and Global Analysis – Product, Application, and Sales Channel," the market is expected to grow from US$ 1,631.92 million in 2021 to US$ 24,266.81 million by 2028; it is estimated to grow at a CAGR of 47.1% from 2021 to 2028.

The report features the major factors driving the market, and prominent players and their advancements in the market. The growth of the non-alcoholic steatohepatitis (NASH) market is mainly determined by the rising prevalence of NASH and increasing initiatives for the awareness of NASH. Nonetheless, the lack of established guidelines for the diagnosis and withdrawal of medications from the marketing authorization stage of clinical trials hamper the market growth.

NASH had the strongest association with COVID-19 of all comorbid metabolic conditions, including hypertension and obesity. Liver injury in the type of increased transaminases and hyperbilirubinemia among COVID-19 patients can be attributed to two or three factors, including prior liver disease. The comorbidity of nonalcoholic fatty liver disease (NAFLD) and NASH in these patients makes them prone to extreme types of liver injury. The presence of fibrosis rather than NASH/NAFLD is associated with more terrible clinical results and higher mortality in COVID-19 patients.

The impact of COVID-19 on comorbid patient populations, including individuals with diabetes, obesity, fatty liver disease, and NASH, has set off the need of providing optimal care to patients. Research revolving around combating NAFLD and NASH indicates that the anticipated relationship with obesity is stark. Therefore, a high incidence of NASH demands advanced diagnostics and treatments, which lifts research and improvement in the market. Thus, the COVID-19 crisis has filled the non-alcoholic steatohepatitis (NASH) market growth.

The non-alcoholic steatohepatitis (NASH) market, by product, is portioned into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib and cenicriviroc, and others. In 2021, the others portion held the largest share of the market. The selonsertib and cenicriviroc fragment is expected to register the fastest CAGR in the non-alcoholic steatohepatitis (NASH) market from 2021 to 2028. Further, the selonsertib and cenicriviroc fragment is anticipated to register the most elevated CAGR of 73.3% in the market during the forecast time frame. Selonsertib is an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. It is being scrutinized in clinical trial NCT03053050 — Safety and Efficacy of Selonsertib in Adults with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Cenicriviroc (CVC) is a strong chemokine 2 and 5 receptor antagonist that is as of now being produced for the treatment of liver fibrosis in individuals with NASH. Various research studies and clinical trials are being conducted overall for selonsertib and CVC, which are expected to drive the market during the forecast time frame.